Table of Contents
The Asia-Pacific internal neurostimulation/neuromodulation market is estimated to register a CAGR of 13.8% between 2014 and 2019. Although the mature market of Japan holds the largest share in the internal neurostimulation/neuromodulation market, India is estimated to register the highest CAGR of 15.3% during the forecast period. The growth of the internal neurostimulation/neuromodulation market in Asia-Pacific is driven by public initiatives to increase awareness, technological developments, growing demand for the use of advanced technologies, and increasingly aging population. However, factors including lack of skilled professional and unfavorable reimbursement scenario are restraining the growth of this market.
In this report, the Asia-Pacific internal neurostimulation/neuromodulation market has been broadly classified into spinal cord stimulator, deep brain stimulator, sacral nerve stimulator, vagus nerve stimulator, and gastric neurostimulator. The Spinal Cord Stimulator segment is further categorized by application into Chronic Pain, Failed Back Surgery Syndrome, Ischemic Pain and others. Likewise, Deep Brain Stimulation market has its application in Parkinson's Disease, Tremor, Depression, and others including Chronic Pain, Dystonia, Tourette's Syndrome, and Alzheimer's disease. Sacral Nerve Stimulation market has applications in Urinary Incontinence and Fecal Incontinence, while Vagus Nerve Stimulator comprises Epilepsy and other applications. Gastric Stimulation includes gastroparesis and others. The gastric neurostimulator market segment is estimated to register the highest CAGR between 2014 and 2019. The driver for this market is the increasing number of people suffering from severe GERD and gastroparesis. Most incidences of delayed bowel movement go unnoticed, which offers a significant growth opportunity for players in this segment.
In terms of countries, Japan is estimated to command the largest share of 53.0% of the Asia-Pacific internal neurostimulation/neuromodulation market in 2014, followed by China. The internal neurostimulation/neuromodulation market in the Japan is primarily driven by factors including aging population, technological advancements, and rising government initiatives.
The Asia-Pacific Internal neurostimulation/neuromodulation market is a competitive market with a number of market players with niche technologies. As of 2014, this market was dominated by Medtronic Inc. (U.S.), St. Jude Medical Inc. (U.S.), Boston Scientific Inc. (U.S.) Depuy Synthes, Inc. (U.S.), Cyberonics Inc. (U.S.), Enteromedics Inc. (U.S.), and Uroplasty, Inc. (U.S.) New product launches and partnerships, agreements, collaborations, and joint ventures are the main strategies adopted by most market players to achieve growth.
Reasons to Buy the Report:
From an insight perspective, this research report focuses on various levels of analysis—industry analysis (industry trends, and PEST analysis), market share analysis of top players, supply chain analysis, and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging and high-growth segments of the Asia-Pacific internal neurostimulation/neuromodulation market, regulatory policies of different countries, government initiatives, drivers, restraints, and upcoming opportunities.
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms in garnering a greater market share. Firms purchasing the report could use any one or combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market share.
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on internal neuromodulation
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Myasthenia Gravis in 26 Major Markets Myasthenia Gravis (MG), also known as autoimmune myasthenia, is one of the most significant diseases ...
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Bell’s palsy in 15 Major Markets Bell's palsy, also known as idiopathic facial nerve palsy, is a weakness of the muscles on one side ...